Biomea Fusion Inc. (BMEA) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Biomea Fusion Inc. (BMEA)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

4.16

0.01 (0.24%)

At close: Jan 14, 2025, 3:59 PM

4.17

0.33%

After-hours Jan 14, 2025, 07:35 PM EST

undefined% (undefined)

Bid	3.9
Market Cap	150.57M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-4.18
PE Ratio (ttm)	-0.99
Forward PE	n/a
Analyst	Buy

Ask	4.15
Volume	535,405
Avg. Volume (20D)	893,311
Open	4.15
Previous Close	4.15
Day's Range	4.01 - 4.25
52-Week Range	3.61 - 20.21
Beta	undefined

About BMEA

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redw...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Apr 16, 2021

Employees 107

Stock Exchange NASDAQ

Ticker Symbol BMEA

Website https://biomeafusion.com

Analyst Forecast

According to 12 analyst ratings, the average rating for BMEA stock is "Buy." The 12-month stock price forecast is $22, which is an increase of 429.48% from the latest price.

Buy 75.00%

Hold 16.67%

Sell 0.00%

Stock Forecasts

Why Price Moved

1 week ago · Source

+2.3%

Biomea Fusion shares are trading higher after the ... Unlock content with Pro Subscription

4 weeks ago · Source

-20.68%

Biomea Fusion shares are trading lower. The company reported Phase II results for Icovamenib in Type 2 diabetes.

News

4 weeks ago · https://thefly.com

Biomea's icovamenib meets HbA1c standards in T2D, says H.C. Wainwright

Biomea on Tuesday announced positive topline results from its Phase 2 COVALENT-111 trial evaluating icovamenib in patients with type 2 diabetes, with key takeaways including icovamenib displaying a st...

4 weeks ago · benzinga.com

Why Is Diabetes-Drug Developer Biomea Fusion Stock Trading Lower On Tuesday?

On Tuesday, Biomea Fusion Inc. BMEA revealed topline results from the ongoing COVALENT-111 study of icovamenib in patients with type 2 diabetes (T2D).